Flexion Therapeutics Inc (NASDAQ:FLXN) – Stock analysts at Oppenheimer lifted their Q3 2020 earnings per share (EPS) estimates for shares of Flexion Therapeutics in a research report issued to clients and investors on Tuesday, October 13th. Oppenheimer analyst F. Brisebois now expects that the specialty pharmaceutical company will post earnings of ($0.51) per share for the quarter, up from their previous forecast of ($0.62). Oppenheimer has a “Outperform” rating and a $19.00 price objective on the stock. Oppenheimer also issued estimates for Flexion Therapeutics’ Q4 2020 earnings at ($0.50) EPS and FY2020 earnings at ($2.73) EPS.
FLXN has been the topic of a number of other reports. Zacks Investment Research raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Flexion Therapeutics in a research report on Thursday, August 6th. Northland Securities began coverage on shares of Flexion Therapeutics in a research report on Thursday, August 6th. They issued a “buy” rating and a $35.00 price objective on the stock. ValuEngine upgraded shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, August 24th. Finally, Goldman Sachs Group began coverage on shares of Flexion Therapeutics in a research report on Thursday, August 20th. They issued a “neutral” rating and a $15.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Flexion Therapeutics presently has a consensus rating of “Buy” and an average price target of $21.64.
NASDAQ:FLXN opened at $13.42 on Friday. The company has a quick ratio of 6.08, a current ratio of 6.60 and a debt-to-equity ratio of 12.77. Flexion Therapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $22.98. The stock has a market cap of $661.65 million, a PE ratio of -3.74 and a beta of 1.92. The firm’s fifty day simple moving average is $11.52 and its 200-day simple moving average is $11.23.
Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings results on Wednesday, August 5th. The specialty pharmaceutical company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.06). The firm had revenue of $15.45 million for the quarter, compared to analyst estimates of $15.46 million.
Large investors have recently added to or reduced their stakes in the business. Schroder Investment Management Group lifted its holdings in Flexion Therapeutics by 3.7% in the 1st quarter. Schroder Investment Management Group now owns 632,823 shares of the specialty pharmaceutical company’s stock valued at $4,904,000 after purchasing an additional 22,633 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Flexion Therapeutics during the 1st quarter worth about $92,000. Dupont Capital Management Corp purchased a new position in shares of Flexion Therapeutics during the 2nd quarter worth about $567,000. Squarepoint Ops LLC lifted its holdings in shares of Flexion Therapeutics by 5.1% during the 1st quarter. Squarepoint Ops LLC now owns 41,043 shares of the specialty pharmaceutical company’s stock worth $323,000 after acquiring an additional 1,987 shares during the period. Finally, Marshall Wace North America L.P. purchased a new position in shares of Flexion Therapeutics during the 2nd quarter worth about $2,328,000. Institutional investors own 90.91% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: How is a management fee different from a performance fee?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.